从研究到临床：探索瑞戈非尼生存获益的优势人群

patients who initiated treatment. NCI-CTCAE, National Cancer mon Terminology Criteria for Adverse Events.?1. Grothey A, et al. Lancet. 2013;381:303–312; 2. Li J, et al. Lancet Oncol. 2015;16:619–629; 3. Grothey A, et al. Presented at: ESMO 17th World Congress on Gastrointestinal Cancer, Jul 1–4, 2015, Barcelona, Spain; 4. Van Cutsem E, et al. Presented at: The ESMO 17th World Congress on Gastrointestinal Cancer, Jul 1–4, 2015, Barcelona, Spain.Р患者比例(%)РCORRECT†1,3РCONCUR†2,3Р瑞戈非尼(n=500)‡Р安慰剂(n=253)‡Р瑞戈非尼(n=136)Р安慰剂(n=68)Р任何级别,不管是否与研究药物有关Р100Р97Р100Р88Р≥3级Р78Р49Р71Р44Р严重Р44Р40Р32Р26Р5级Р13Р15Р9Р10Р导致治疗终止Р18Р13Р14Р6Р导致剂量减少Р38Р3Р40Р0Р导致治疗中断Р61Р22Р63Р16Р任何级别,药物相关Р93Р61Р97Р46Р≥3级Р55Р14Р54Р15Р5级Р1Р0Р1Р0Р治疗相关不良事件*Р10РGrothey A, et al Lancet 2013381:303–312 ?Li J, et al Lancet Oncol 2015;16:619–629